Escalating protein supersaturation underlies inclusion formation in muscle proteinopathies

Prajwal Ciryam, Matthew Antalek, Fernando Maureira Cid, Gian Gaetano Tartaglia, Christopher M. Dobson, Anne‐Katrin Güttsches, Britta Eggers, Matthias Vorgerd, Katrin Marcus, Rudolf A. Kley, Richard I. Morimoto, Michele Vendruscolo, Conrad C. WeihlbioRxiv 2019 · DOI

TL;DR

This study reveals that protein "supersaturation" – a state where protein concentration exceeds solubility – is a key driver of protein aggregate formation in muscle diseases, not just neurodegeneration. By analyzing muscle biopsies, researchers found that this supersaturation escalates as it approaches protein inclusions, suggesting a failure in cellular regulation that leads to disease.

What Problem Does This Paper Address?

Protein aggregates are hallmarks of many age-related degenerative diseases, including neurodegenerative disorders and protein aggregate myopathies (PAMs). While the concept of protein "supersaturation" has been linked to aggregation in the brain, its role in non-neuronal protein conformational disorders like PAMs remained unclear. This paper investigates whether escalating protein supersaturation is a unifying mechanism underlying the formation of protein inclusions in muscle diseases, and how this process unfolds at a cellular level.

Methods

The researchers employed a multi-faceted approach:

  • Laser Microdissection (LMD): This technique allowed them to precisely isolate specific regions of muscle fibers from patient biopsies, including healthy control fibers (HC), unaffected fibers in diseased patients (DC), affected fibers surrounding inclusions (AF), and the inclusion bodies themselves (rimmed vacuoles, RV).
  • Mass Spectrometry (MS): Label-free spectral count-based relative protein quantification was used to analyze the protein composition of these isolated cellular regions.
  • Proteomic Analysis: This involved comparing the protein profiles of different tissue regions to identify proteins enriched in inclusion bodies and to quantify their abundance.
  • Supersaturation Scoring: The core of their analysis involved calculating "supersaturation scores" for thousands of proteins. This metric combines a protein's predicted aggregation propensity (based on its amino acid sequence) with its measured expression level. They used two versions:
  • Unfolded Supersaturation Score ($\sigma_u$): Based on predicted aggregation propensity of unfolded proteins and expression levels.
  • Folded Supersaturation Score ($\sigma_f$): Similar to $\sigma_u$ but incorporates a more refined prediction of aggregation propensity considering protein folding.

Datasets

The study utilized proteomic datasets derived from human biopsy specimens of patients with various protein aggregate myopathies (PAMs), including:

  • Inclusion Body Myositis (IBM) patients.
  • Hereditary PAMs (hPAMs) patients with mutations in DES (desminopathy), FLNC (filaminopathy), and MYOT (myotilinopathy) genes.

These datasets were compared with healthy control muscle tissue. No new benchmark datasets were introduced; rather, existing patient-derived samples were analyzed.

Key Insights and Ideas

  • Supersaturation is a Universal Driver: The principle of protein supersaturation isn't confined to neurodegeneration; it's a critical factor in muscle proteinopathies as well.
  • Escalation is Key: It's not just being supersaturated, but the escalation of supersaturation as one approaches protein inclusions that drives aggregation. This suggests a progressive breakdown of cellular control.
  • "Escape" Proteins: Some supersaturated proteins appear to "escape" normal regulatory mechanisms (like downregulation), leading to their accumulation in inclusions. Desmin is highlighted as a prime example.
  • Muscle as a Model: Muscle tissue, being more accessible than brain tissue, offers a unique window into how proteinopathies remodel specific tissues and the role of supersaturation in disease progression.

Key Results

  • Elevated Supersaturation in PAMs: Proteins found in rimmed vacuoles (RVs) and inclusions in PAMs, including IBM and hereditary forms, show significantly elevated supersaturation scores even in healthy muscle tissue.
  • Progressive Escalation: In IBM, supersaturation scores for RV-enriched proteins increase progressively from healthy control fibers to unaffected diseased fibers, to affected fibers, and finally to the rimmed vacuoles themselves. This escalation was statistically significant.
  • Hereditary PAMs Mirror IBM: Similar escalating supersaturation patterns were observed in hereditary PAMs, indicating a common underlying mechanism across different genetic causes.
  • Downregulation Failure: While many supersaturated proteins are downregulated in affected muscle fibers, RV-enriched proteins, particularly desmin, tend to increase in abundance, suggesting a failure of this regulatory mechanism.
  • Desmin as a Key Player: Desmin, a protein found to be both supersaturated in healthy tissue and to increase in abundance during disease progression, emerges as a potential therapeutic target.

Limitations and Future Work

  • Tissue Specificity: While the study uses tissue-specific supersaturation scores, the initial analysis of unfolded supersaturation scores ($\sigma_u$) was based on average abundances across various tissues, lacking fine-grained tissue specificity.
  • Sample Size Limitations: For some individual hereditary PAMs, sample size limitations led to statistically insignificant results for certain supersaturation metrics.
  • Therapeutic Implications: The findings suggest that therapies aimed at reducing the abundance of these supersaturated proteins or buffering the metastable proteome could be effective in treating PAMs. Desmin is identified as a potential target for intervention.
  • Biomarker Potential: The degree of supersaturation of specific protein subsets could serve as a biomarker for the proteostatic state of muscle.

Summary updated

Abstract

Abstract Abundant, aggregation prone or “supersaturated” proteins are a feature of neurodegeneration. Whether the principle of supersaturation can similarly explain the widespread aggregation that occurs in non-neuronal protein conformational disorders and underlies pathogenic protein aggregate formation is not established. To test this prediction we analyzed proteomic datasets of biopsies from genetic and acquired protein aggregate myopathy (PAM) patients by quantifying the changes in composition, concentration and aggregation propensity of proteins in the fibers containing inclusions and those surrounding them. We found that similar to neurodegeneration, a supersaturated subproteome of aggregate prone proteins is present in skeletal muscle from healthy patients. This subproteome escalates in degree of supersaturation as proteomic samples are taken more proximal to the pathologic inclusion, eventually exceeding its solubility limits and aggregating. While most supersaturated proteins decrease or maintain steady abundance across healthy fibers and inclusion containing fibers, supersaturated proteins within the aggregate subproteome rise in abundance, suggesting they escape normal regulation. We show in the context of a human conformational disorder that the level of supersaturation of a metastable subproteome helps to explain widespread aggregation and correlates with the histopathological state of the tissue. Significance Increasing evidence implicates the phenomenon of protein supersaturation with the selective vulnerability of specific cells to protein misfolding disorders. Quantitative studies of this phenomenon, however, have only been possible post mortem in the case of neurodegenerative diseases. To overcome this limitation, we study here protein aggregate myopathies (PAMs), for which we were able to carry out systematic single fiber proteomic studies on patient-derived samples. We found not only that proteins associated with PAM inclusions are highly supersaturated in muscle but also that their supersaturation levels increases further in affected fibers. These results provide a clear illustration of how an escalation in supersaturation leads protein inclusions in vulnerable cells.
BibTeX
@misc{ciryam2019escalating,
  author = {Prajwal Ciryam and Matthew Antalek and Fernando Maureira Cid and Gian Gaetano Tartaglia and Christopher M. Dobson and Anne‐Katrin Güttsches and Britta Eggers and Matthias Vorgerd and Katrin Marcus and Rudolf A. Kley and Richard I. Morimoto and Michele Vendruscolo and Conrad C. Weihl},
  title = {{Escalating protein supersaturation underlies inclusion formation in muscle proteinopathies}},
  year = {2019},
  doi = {10.1101/762245},
  howpublished = {bioRxiv},
}
Figure